▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / CELZ

CELZ — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1187953 ·
Last close
$1.21
Market Cap
$7.98M
52W High
$4.72
52W Low
$0.62
ADV30
13,517,220
Next earnings
—
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 0 -1,459,153 -1,405,077 6,440,577 5,723,176 307,649
Dec 2025 3,000 2,006 -1,945,782 -1,887,674 7,809,525 7,208,126 284,880
Sep 2025 0 0 -1,273,034 -1,235,934 5,853,003 5,375,511 261,353
Jun 2025 0 0 -1,263,520 -1,233,303 7,105,228 6,544,120 277,644

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,588,220
Investing CF
$-225,500
Financing CF
$3,834,029
CapEx
$-125,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.17
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-71,991,998
Inventory
$0
Receivables
$105,711
ST Investments
$125,000
EBIT TTM
$-5,941,489
Pretax Income TTM
$-5,760,628
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,000
EBITDA
$-6,126,351
Free Cash Flow
$-3,456,562
Enterprise Value
$-164,585
Total Cash
$8,839,115
Total Debt
$14,194
Shares Out
6,592,557
Trailing EPS
$-2.05
Book Value
$1.33
ROE
-77.9%
ROA
-47.3%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 6,000 -6,142,814 -5,995,008 7,809,525 284,880 — -5,856,445
Dec 2024 11,000 -5,743,861 -5,493,481 6,669,143 327,644 — -5,301,292
Dec 2023 9,000 -5,620,132 -5,286,574 10,715,190 371,394 — -8,027,885
Dec 2022 88,600 -10,244,372 -10,144,044 19,186,326 3,321,652 — -7,796,966

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.88

Peers — same industry

TickerNameMarket CapLastDaily %
AIM AIM ImmunoTech Inc. $7.73M $0.25 —
CUBT Curative Biotechnology Inc $8.89M $1.00 —
LIMN Liminatus Pharma, Inc. $6.27M $4.67 —
BCLI BRAINSTORM CELL THERAPEUTICS INC. $11.03M $1.00 —
ZEOX Zeo ScientifiX, Inc. $11.29M $1.44 —

News headlines (Yahoo Finance, 1h cache)

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluat
2026-08-20 13:15 · Yahoo
Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy
2026-08-06 15:04 · Yahoo
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CEL
2026-08-06 13:15 · Yahoo
Creative Medical Technology Holdings Issues Mid-Year Update
2026-07-01 13:00 · Yahoo
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
2026-06-30 18:07 · Yahoo
These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism?
2026-06-26 17:54 · Yahoo
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
2026-06-22 13:15 · Yahoo
Creative Medical Technology opens nationwide burn-pit data registry
2026-06-16 19:49 · Yahoo
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
2026-06-16 13:00 · Yahoo
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
2026-04-28 13:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →